Srikripa Devarakonda
Stock Analyst at Truist Securities
(2.70)
# 2,014
Out of 4,734 analysts
54
Total ratings
32.08%
Success rate
1.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,126 → $1,004 | $681.58 | +47.30% | 5 | Jan 8, 2025 | |
| BIIB Biogen | Maintains: Buy | $302 → $220 | $140.55 | +56.53% | 2 | Jan 8, 2025 | |
| ABBV AbbVie | Maintains: Buy | $215 → $211 | $171.56 | +22.99% | 2 | Jan 8, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $100 → $43 | $10.86 | +295.95% | 4 | Dec 23, 2024 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $26.30 | +21.67% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $26.26 | +90.40% | 6 | Nov 27, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $36 → $45 | $43.13 | +4.34% | 4 | Nov 25, 2024 | |
| KYMR Kymera Therapeutics | Reiterates: Buy | $54 → $53 | $40.61 | +30.51% | 3 | Nov 1, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $1,000 → $1,033 | $725.72 | +42.34% | 3 | Oct 10, 2024 | |
| BMEA Biomea Fusion | Upgrades: Buy | $54 | $3.98 | +1,258.49% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $83 → $74 | $71.93 | +2.88% | 8 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $36.82 | +62.95% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.33 | +181.43% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $19.14 | +88.09% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $45.74 | +53.04% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $60 | $1.15 | +5,117.39% | 2 | Aug 11, 2023 |
Regeneron Pharmaceuticals
Jan 8, 2025
Maintains: Buy
Price Target: $1,126 → $1,004
Current: $681.58
Upside: +47.30%
Biogen
Jan 8, 2025
Maintains: Buy
Price Target: $302 → $220
Current: $140.55
Upside: +56.53%
AbbVie
Jan 8, 2025
Maintains: Buy
Price Target: $215 → $211
Current: $171.56
Upside: +22.99%
Keros Therapeutics
Dec 23, 2024
Maintains: Buy
Price Target: $100 → $43
Current: $10.86
Upside: +295.95%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $26.30
Upside: +21.67%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $26.26
Upside: +90.40%
Scholar Rock Holding
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $43.13
Upside: +4.34%
Kymera Therapeutics
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $40.61
Upside: +30.51%
Eli Lilly
Oct 10, 2024
Maintains: Buy
Price Target: $1,000 → $1,033
Current: $725.72
Upside: +42.34%
Biomea Fusion
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $3.98
Upside: +1,258.49%
Sep 18, 2024
Downgrades: Hold
Price Target: $83 → $74
Current: $71.93
Upside: +2.88%
Sep 9, 2024
Initiates: Buy
Price Target: $60
Current: $36.82
Upside: +62.95%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $5.33
Upside: +181.43%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $19.14
Upside: +88.09%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $45.74
Upside: +53.04%
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $1.15
Upside: +5,117.39%